Scarisbrick, J., Querfeld, C., Akilov, O., Bagot, M., Córdoba, R., Cowan, R., Garcia-Sancho, A. M., Geskin, L., Huen, A., Morris, S., Ortiz-Romero, P., Pinter-Brown, L., Pujol, R., Quaglino, P., Saba, N., Shiue, L., Jadwani, J., Liu, Y., Arora, P., Zhao, H., Vuppugalla, R., Kim, Y. (2025). A Phase 2, multicenter, open-label, single-arm study assessing a 4-weekly dosing schedule for mogamulizumab in patients with mycosis fungoides/Sézary syndrome (MOGA-2MG-Q4W). Blood. https://doi.org/10.1182/blood-2025-1875